Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 ADMA BiologicsGamida CellAxcella HealthINmune BioFennec Pharmaceuticals
SymbolNASDAQ:ADMANASDAQ:GMDANASDAQ:AXLANASDAQ:INMBNASDAQ:FENC
Price Information
Current Price$1.65$7.65$4.25$13.62$6.27
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.41.61.51.5
Analysis Score3.53.53.43.53.5
Community Score3.02.72.83.32.5
Dividend Score0.00.00.00.00.0
Ownership Score0.80.01.70.80.8
Earnings & Valuation Score0.60.60.00.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$7.80$20.25$16.13$19.25$14.67
% Upside from Price Target372.73% upside164.71% upside279.41% upside41.34% upside133.92% upside
Trade Information
Market Cap$200.10 million$185.28 million$160.18 million$203.39 million$163.04 million
Beta1.842.031.533.010.07
Average Volume3,523,552913,55780,315295,624100,608
Sales & Book Value
Annual Revenue$29.35 millionN/AN/AN/AN/A
Price / Sales6.82N/AN/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.44 per share$1.44 per share$2.61 per share$2.19 per share$0.60 per share
Price / Book3.75N/AN/AN/AN/A
Profitability
Net Income$-48,280,000.00$-34,350,000.00$-59,040,000.00$-7,680,000.00$-12,770,000.00
EPS($0.92)($1.69)($3.55)($0.75)($0.64)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A5.55
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-166.01%N/AN/AN/AN/A
Return on Equity (ROE)-98.83%-112.47%-79.03%-41.18%-84.34%
Return on Assets (ROA)-37.21%-65.09%-54.77%-39.34%-75.51%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio1.40%N/A0.28%N/AN/A
Current Ratio8.47%5.39%22.66%17.73%11.81%
Quick Ratio4.24%5.39%22.66%17.73%11.81%
Ownership Information
Institutional Ownership Percentage48.90%N/A66.77%7.38%53.58%
Insider Ownership Percentage11.70%N/A10.40%58.87%9.08%
Miscellaneous
Employees313110594N/A
Shares Outstanding121.28 million24.22 million37.69 million14.93 million26.00 million
Next Earnings Date5/5/2021 (Estimated)5/20/2021 (Estimated)5/10/2021 (Estimated)5/13/2021 (Estimated)5/13/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
 Brokerages Expect Fennec Pharmaceuticals Inc (NASDAQ:FENC) Will Announce Earnings of -$0.01 Per Share Brokerages Expect Fennec Pharmaceuticals Inc (NASDAQ:FENC) Will Announce Earnings of -$0.01 Per Share
americanbankingnews.com - April 8 at 4:20 PM
Analysts Are Optimistic Well See A Profit From Fennec Pharmaceuticals Inc. (NASDAQ:FENC)Analysts Are Optimistic We'll See A Profit From Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
finance.yahoo.com - April 4 at 12:40 PM
Cantor Fitzgerald Equities Analysts Reduce Earnings Estimates for Fennec Pharmaceuticals Inc (NASDAQ:FENC)Cantor Fitzgerald Equities Analysts Reduce Earnings Estimates for Fennec Pharmaceuticals Inc (NASDAQ:FENC)
americanbankingnews.com - April 2 at 8:50 AM
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Forecasted to Post Q1 2021 Earnings of ($0.12) Per ShareFennec Pharmaceuticals Inc (NASDAQ:FENC) Forecasted to Post Q1 2021 Earnings of ($0.12) Per Share
americanbankingnews.com - April 2 at 7:58 AM
FY2021 Earnings Forecast for Fennec Pharmaceuticals Inc Issued By Wedbush (NASDAQ:FENC)FY2021 Earnings Forecast for Fennec Pharmaceuticals Inc Issued By Wedbush (NASDAQ:FENC)
americanbankingnews.com - April 1 at 8:18 AM
Fennec Pharmaceuticals (NASDAQ:FENC) Posts Quarterly  Earnings Results, Beats Expectations By $0.06 EPSFennec Pharmaceuticals (NASDAQ:FENC) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS
americanbankingnews.com - March 31 at 7:50 AM
What Type Of Shareholders Make Up Fennec Pharmaceuticals Inc.s (NASDAQ:FENC) Share Registry?What Type Of Shareholders Make Up Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Registry?
finance.yahoo.com - February 3 at 8:50 AM
NASDAQ:FENC Long Term Investor Notice: Investigation of Potential Wrongdoing at Fennec Pharmaceuticals Inc.NASDAQ:FENC Long Term Investor Notice: Investigation of Potential Wrongdoing at Fennec Pharmaceuticals Inc.
sbwire.com - December 15 at 1:41 PM
Investigation announced for Long-Term Investors in shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC)Investigation announced for Long-Term Investors in shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC)
openpr.com - December 11 at 3:38 PM
Fennec Pharmaceuticals EPS misses by $0.05Fennec Pharmaceuticals EPS misses by $0.05
seekingalpha.com - November 16 at 8:39 AM
Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business UpdateFennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - November 16 at 8:39 AM
BioMedNewsBreaks - Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Board Appointment of Dr. Khalid IslamBioMedNewsBreaks - Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Board Appointment of Dr. Khalid Islam
marketwatch.com - November 6 at 4:45 PM
Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of DirectorsProcessa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors
news.yahoo.com - November 5 at 12:40 PM
Fennec Pharmaceuticals: The Compensation Is Whats MissingFennec Pharmaceuticals: The Compensation Is What's Missing
seekingalpha.com - November 5 at 12:40 PM
NOVEMBER 2 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNOVEMBER 2 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - November 2 at 2:32 AM
FINAL DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Reminds Fennec Pharmaceuticals Inc. Investors of the Important November 2 Deadline in Securities Class Action – FENCFINAL DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Reminds Fennec Pharmaceuticals Inc. Investors of the Important November 2 Deadline in Securities Class Action – FENC
feeds.benzinga.com - November 1 at 3:55 PM
FENC Final Deadline Alert: Rosen, Top Ranked Global Counsel, Reminds Fennec Pharmaceuticals Inc. Investors of the Important November 2 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - FENCFENC Final Deadline Alert: Rosen, Top Ranked Global Counsel, Reminds Fennec Pharmaceuticals Inc. Investors of the Important November 2 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - FENC
finance.yahoo.com - October 30 at 9:32 PM
LAWSUITS FILED AGAINST FENC, BMRN and CACC - Jakubowitz Law Pursues Shareholders ClaimsLAWSUITS FILED AGAINST FENC, BMRN and CACC - Jakubowitz Law Pursues Shareholders Claims
finance.yahoo.com - October 30 at 9:32 PM
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Fennec Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmDEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Fennec Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
finance.yahoo.com - October 30 at 9:32 PM
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fennec Pharmaceuticals Inc. (FENC)The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fennec Pharmaceuticals Inc. (FENC)
businesswire.com - October 30 at 12:02 PM
FINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Fennec Pharmaceuticals Inc. Investors of the Important November 2 Deadline in Securities Class Action - FENCFINAL DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Fennec Pharmaceuticals Inc. Investors of the Important November 2 Deadline in Securities Class Action - FENC
finance.yahoo.com - October 28 at 7:44 PM
FINAL DEADLINE THIS MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmFINAL DEADLINE THIS MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - October 27 at 1:07 PM
UPLCQ, FENC & HDB Class Action Reminders: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class ActionsUPLCQ, FENC & HDB Class Action Reminders: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions
finance.yahoo.com - October 27 at 1:07 PM
FINAL DEADLINE NEXT WEEK: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmFINAL DEADLINE NEXT WEEK: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - October 26 at 4:45 PM
SHAREHOLDER ALERT: FENC NXTC RETA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action DeadlinesSHAREHOLDER ALERT: FENC NXTC RETA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
finance.yahoo.com - October 22 at 7:49 PM
DateCompanyBrokerageAction
4/5/2021ADMA BiologicsJefferies Financial GroupReiterated Rating
4/1/2021ADMA BiologicsRaymond JamesLower Price Target
3/26/2021ADMA BiologicsMaxim GroupReiterated Rating
1/4/2021ADMA BiologicsHC WainwrightLower Price Target
8/6/2020ADMA BiologicsOppenheimerInitiated Coverage
8/12/2019ADMA BiologicsDawson JamesDowngrade
4/4/2019ADMA BiologicsWBB SecuritiesUpgrade
3/15/2021Gamida CellNeedham & Company LLCLower Price Target
3/9/2021Gamida CellPiper SandlerLower Price Target
6/30/2020Gamida CellEvercore ISIInitiated Coverage
2/26/2020Gamida CellBMO Capital MarketsLower Price Target
9/20/2019Gamida CellJMP SecuritiesInitiated Coverage
11/21/2018Gamida CellCIBCInitiated Coverage
3/20/2021Axcella HealthWedbushReiterated Rating
11/26/2020Axcella HealthChardan CapitalReiterated Rating
11/18/2020Axcella HealthRoth CapitalInitiated Coverage
10/26/2020Axcella HealthSVB LeerinkReiterated Rating
10/14/2020Axcella HealthJPMorgan Chase & Co.Initiated Coverage
9/25/2020Axcella HealthB. RileyInitiated Coverage
8/12/2020Axcella HealthThe Goldman Sachs GroupReiterated Rating
7/9/2020Axcella HealthBTIG ResearchLower Price Target
6/4/2020Fennec PharmaceuticalsCantor FitzgeraldInitiated Coverage
(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.